×

MonoSol Rx Changes Name to Aquestive Therapeutics and Expands CNS Product Portfolio

WARREN, N.J., Nov. 30, 2017 /PRNewswire/ -- MonoSol Rx today announced the change of its corporate name to Aquestive Therapeutics (Aquestive). The new name reflects the company's expanded capabilities in developing and commercializing a proprietary portfolio of medicines, initially focused on the central nervous system (CNS).

"As we prepare to seek approval and eventually commercialize products, it is important to capture the significant change in our business by transitioning to a new corporate name that portrays who we are and where we are going as a specialty pharmaceutical company with both powerful R&D and commercial capabilities. Ultimately, this will allow us to deliver to patients advanced treatments that can meaningfully improve their lives," said Keith J. Kendall, Chief Executive Officer of Aquestive. "Our recent NDA filing for clobazam, one of our three late-stage CNS products, is not only an example of the Company's growth, but underscores our commitment to leveraging our expertise and proprietary technologies to address true unmet needs in the marketplace."

Since its founding in 2004, Aquestive has been the undisputed leader in developing and delivering drugs through its proprietary technologies. The Company is currently the exclusive global manufacturer of Suboxone® sublingual film (buprenorphine and naloxone) and Zuplenz® oral soluble film (ondansetron). Aquestive has products in development to treat epilepsy, amyotrophic lateral sclerosis (ALS) and anxiety/panic disorders.

About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people's lives. Aquestive is committed to addressing immediate CNS challenges by furthering its strong pipeline of products. As the undisputed leader in developing and delivering drugs via its proprietary technologies, the Company also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. For more information, please visit aquestive.com.

Media inquiries:
Christopher Hippolyte
christopher.hippolyte@inventivhealth.com
212-364-0458

Investor inquiries:
Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282

View original content with multimedia:http://www.prnewswire.com/news-releases/monosol-rx-changes-name-to-aquestive-therapeutics-and-expands-cns-product-portfolio-300564299.html

SOURCE Aquestive Therapeutics